Japan's Daiichi Sankyo to sell up to $3.6 billion Sun Pharma stake
By Abhishek Vishnoi MUMBAI (Reuters) – Japan’s Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd , setting it on course to retreat from India after a rollercoaster seven years. Daiichi Sankyo bought India’s Ranbaxy Laboratories in 2008, betting on growing global demand for generic drugs, but found itself saddled with a company battling complaints and sanctions from the U.S.
From start to finish, here’s how hitting the pavement affects you mentally and physically.
A new study suggests it’s possible to sniff emotions in sweat.
On Sunday, Miley Cyrus shocked her followers by posting a photo of herself with armpit hair. Here’s the weird reason we’re programed to be repelled by it.
Team news for Tuesday’s League One clash between Notts County and Preston North End at Meadow Lane.
Lewis Hornby will not be offered a new deal by Northampton, manager Chris Wilder has confirmed.
Former head of international cycling Hein Verbruggen says he will fight any attempt to remove him as honorary president of the Union Cycliste Internationale (UCI).
Portsmouth have hinted they could wait until the end of May before appointing their new manager.
Jump jockey Daragh Bourke is to face the disciplinary panel of the British Horseracing Authority on Thursday after failing a drugs test.
Promotional image by Yoox, an ecommerce platform that recently merged with Net-A-Porter Maintaining an in-house ecommerce platform is highly demanding, making a cloud-based solution the shrewdest move for brands lacking serious cash-flow and a digitally-oriented management team, according to a new report by L2 and Demandware. Trailblazing brands such as Burberry and Gucci adopted in-house ecommerce platforms early on and are now seeing their investments stagnate as brands with cloud-based platforms
